Get the current market trends in your inbox
Stay on top of the most recent market patterns and economic insights with the Axios Markets newsletter. Register for totally free.
Capture up on coronavirus stories and unique reports, curated by Mike Allen everyday
Catch up on coronavirus stories and unique reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories impacting your hometown with Axios Denver
Des Moines news in your inbox
Capture up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most essential stories impacting your home town with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories impacting your hometown with Axios Tampa-St. Petersburg
Illustration: Annelise Capossela/Axios
The Fda on Tuesday authorized the first non-prescription, at-home fast coronavirus test, which enables users to get their results from an app.
The big picture: A slew of at-home tests are in advancement, which could make diagnostics much easier and quicker as the pandemic rages on.
The state of play: A number of business are dealing with at-home test kits that provide results digitally, the Wall Street Journal notes
- Ellume, the company that got FDA permission for its at-home test on Tuesday, is dealing with a function that would let users share their outcomes with their medical professional and local health authorities.
- The FDA asked Lucira Health, which is working on a fast test, to establish a mobile app or site for better information tracking.
- Gauss Surgical and Cellex’s test would require users take a photo of their outcomes for an algorithm’s interpretation.
- On Wednesday, the BinaxNOW COVID-19 Ag Card House Test was licensed for use by clients at house with a prescription, and will be coupled with telehealth choices.
No comments:
Post a Comment